ASNC

Gaxos Health Forms Medical Advisory Board to Support Launch of AI-powered Health and Wellness Solution

Retrieved on: 
Wednesday, February 28, 2024
Advisory board, Lipid, Weill Cornell Medicine, Intelligence, MD, Obesity, National Lipid Association, Cardiothoracic surgery, Hospital, Plaque, Hackensack University Medical Center, Yale University, Society, Helsinki University Central Hospital, Health, ASNC, American College, Internal medicine, Journal, Medicine, Medical Center, Research, Veterinary medicine

“The establishment of our Medical Advisory Board reflects our commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI.

Key Points: 
  • “The establishment of our Medical Advisory Board reflects our commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI.
  • He is an attending cardiologist at Hackensack University Medical Center’s Heart and Vascular Hospital where he is director of lipids and preventive cardiology.
  • Dr. Lebowitz received his MD from Cornell University Medical College (now Weill-Cornell Medical College) in New York.
  • “We welcome Dr. Lebowitz to the advisory board as his experience and talents will be invaluable to the creation of our solution,” Vadim Mats added.

Lawrence Phillips, MD, FASNC, Installed as ASNC's President for 2024

Retrieved on: 
Monday, January 8, 2024
Editorial, Cardiology, Past, North Shore University Hospital, Master of Science, Message, Thomas Jefferson University, Doctor of Philosophy, NYU, Society, Health policy, News, NYU Langone Health, Moyamoya disease, Patient, Diagnosis, ASNC, Medicine, Journal, MHS, Medical imaging

FAIRFAX, Va., Jan. 8, 2024 /PRNewswire/ -- Lawrence Phillips, MD, FASNC, director of nuclear cardiology and medical director for outpatient cardiology at NYU Langone Health, was installed as president of the American Society of Nuclear Cardiology (ASNC). He will serve as leader of the organization for the next year. Dr. Phillips is an associate professor of medicine in the Leon H. Charney Division of Cardiology and associate director of the training program in cardiovascular diseases at NYU Grossman School of Medicine. He launched his presidential term with an editorial urging nuclear cardiology professionals to view their field as "a team sport" and embrace education and quality improvement efforts that will unlock the field's potential for the future. His President's Message is published online in the Journal of Nuclear Cardiology.

Key Points: 
  • FAIRFAX, Va., Jan. 8, 2024 /PRNewswire/ -- Lawrence Phillips, MD, FASNC, director of nuclear cardiology and medical director for outpatient cardiology at NYU Langone Health, was installed as president of the American Society of Nuclear Cardiology (ASNC).
  • His President's Message is published online in the Journal of Nuclear Cardiology.
  • He completed his internal medicine residency and cardiovascular training fellowship at North Shore University Hospital in New York.
  • For nuclear cardiology news, follow Dr. Phillips on X (formerly Twitter) at @LPhillipsMD and @MyASNC.

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology

Retrieved on: 
Monday, October 2, 2023
Columbia University, Columbia University Irving Medical Center, Male, ASNC, LV, LVH, N-terminal prohormone of brain natriuretic peptide, Cardiac amyloidosis, Serum, Secondary systemic amyloidosis, Echocardiography, IQR, Hypertrophic cardiomyopathy, ID, Assistant, SUV, ICC, ECV, CMP, ATTR, SAN, Map, Cardiology, Amyloidosis, Oregon Health and Science University Center for Women's Health, PET/CT, Genetic testing, Diagnosis, Liver, CMR, HCM, Society, Arnold, Disease, Medical imaging, Medical device, Hospital, Medicine, Patient, Heart

Attralus-Sponsored Test-Retest repeatability study demonstrates excellent repeatability and supports the potential use of AT-01 imaging to monitor disease progression in patients with cardiac amyloidosis.

Key Points: 
  • Attralus-Sponsored Test-Retest repeatability study demonstrates excellent repeatability and supports the potential use of AT-01 imaging to monitor disease progression in patients with cardiac amyloidosis.
  • AT-01 uptake in cardiac amyloidosis shows moderate and statistically significant correlations with traditional measures of cardiac structure and function.
  • These data were included in oral and poster presentations at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC) taking place September 29-October 1, 2023, in Toronto, Canada.
  • These findings support the potential use of this novel imaging agent to monitor disease progression in patients with cardiac amyloidosis.

Jubilant Radiopharma and Cardiac Imaging, Inc. Announce Exclusive Partnership to Expand Access for Mobile Cardiac PET Offering

Retrieved on: 
Friday, September 29, 2023
Hospitals, Health, Radiology, Pharmaceutical, Cardiology, Learning, Cardiac imaging, ASNC, Partnership, Cardiac PET, CAD, PET, Westin Harbour Castle Hotel, Patient, Physician, Society, Heart, Hospital, Jubilant

Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.

Key Points: 
  • Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.
  • “This partnership with Cardiac Imaging allows unprecedented access of RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator) to various types of facilities interested in performing cardiac PET,” said Sergio Calvo, President, Jubilant Radiopharma, Radiopharmaceuticals Division.
  • Cardiac Imaging, Inc.’s fixed site program is a comprehensive turnkey offering, enabling physicians to administer Cardiac PET in their own facilities.
  • Through these solutions, Cardiac Imaging, Inc. is advancing the field of cardiac PET and delivering premier cardiac care across the US.

Media Alert: ASNC Publishes New Model Coverage Policy for Cardiac PET Imaging

Retrieved on: 
Thursday, September 7, 2023
Infection, ASNC, Medicaid, Houston Methodist Hospital, Table, Morristown Medical Center, Policy, PET, Inflammation, Doctor of Philosophy, Medicare, Literature, Journal, Sarcoidosis, Patient, Physician, Master of Science, Journal of Nuclear Cardiology, Cardiology, Rush University Medical Center, Society, Health insurance, Medical device, Medical imaging, MD

FAIRFAX, Va., Sept. 7, 2023 /PRNewswire/ -- To encourage consistent and correct coverage policies for cardiac positron emission tomography (PET), the American Society of Nuclear Cardiology (ASNC) has developed a new model coverage policy that defines several categories of clinical indications where cardiac PET and myocardial blood flow assessment should be universally covered by Medicare contractors, Medicaid programs and private payers. By compiling the current evidence supporting medical necessity for each indication, ASNC aims to help payers eliminate unnecessary prior authorization requirements that can lead to dangerous care delays and denials.

Key Points: 
  • FAIRFAX, Va., Sept. 7, 2023 /PRNewswire/ -- To encourage consistent and correct coverage policies for cardiac positron emission tomography (PET), the American Society of Nuclear Cardiology (ASNC) has developed a new model coverage policy that defines several categories of clinical indications where cardiac PET and myocardial blood flow assessment should be universally covered by Medicare contractors, Medicaid programs and private payers.
  • "ASNC's new model coverage policy describes each clinical situation where a cardiac PET study is currently indicated, including symptoms, references and cross-references to the appropriate use criteria."
  • In this way, ASNC intends for the model coverage policy to function as a helpful resource for the cardiology community, referring physicians and their billing/coding staff.
  • "The ASNC Model Coverage Policy: 2023 Cardiac Positron Emission Tomography" was developed by a team of leading authorities in cardiac PET imaging and myocardial blood flow assessment.

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Retrieved on: 
Tuesday, September 13, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Clinical Trials, Photon, Single-photon emission computed tomography, Half-life, American Society of Nuclear Cardiology, St. Luke's Hospital, Development, Molecular imaging, Thomas Edison, Twitter, NYSE, MPI, Phase, Research, Hospital, LinkedIn, Society, News, Coronary artery disease, Patient, Intelligence, PET, LNTH, 18F, Luke the Evangelist, Myocardial perfusion imaging, Research and development, Cardiology, Doctor of Philosophy, CAD, Ecosystem, NASDAQ, Death, Neurology, SPECT, GE Healthcare, Congress, Multimedia, ASNC, FACC, Positron emission tomography, Medical imaging, Pharmaceutical industry, MD, Facebook

GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD).

Key Points: 
  • GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD).
  • Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.
  • This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Retrieved on: 
Tuesday, September 13, 2022
Photon, Single-photon emission computed tomography, Half-life, NORTH, American Society of Nuclear Cardiology, St. Luke's Hospital, Development, Molecular imaging, Thomas Edison, Twitter, NYSE, MPI, Phase, Research, Hospital, LinkedIn, Society, News, Coronary artery disease, Program, Patient, Intelligence, PET, LNTH, 18F, Myocardial perfusion imaging, Luke the Evangelist, Research and development, Cardiology, Doctor of Philosophy, CAD, Ecosystem, NASDAQ, Death, Neurology, SPECT, GLOBE, GE Healthcare, Congress, ASNC, FACC, Positron emission tomography, Medical imaging, Pharmaceutical industry, MD, Facebook

Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.

Key Points: 
  • Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.
  • This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.
  • GE Healthcare has led the funding and development of [18F]flurpiridaz, and, if the imaging agent is approved, will have global commercialization rights.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

Attralus Announces New Clinical Data in ATTR CM and AL With AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent

Retrieved on: 
Monday, September 12, 2022
AL, MPH, IQR, American Society of Nuclear Cardiology, Therapy, LV, ATTR, Iodine, CMP, PET/CT, AT-02, Cardiomyopathy, Society, Degenerative disease, Patient, Forward-looking statement, PET, Liver, Nuclear, Diagnosis, Tissue, SAN, Heart, ISA, GLOBE, ASNC, Awareness, University, Kidney, Spleen, PAR, International Symposium on Endovascular Therapy, Holding company, Medical imaging, Surface finishing, MD, Amyloidosis, Brigham

"In this pilot study, AT-01 demonstrated itself as a valuable tool for the quantification of cardiac amyloid burden in both ATTR and AL cardiomyopathy.

Key Points: 
  • "In this pilot study, AT-01 demonstrated itself as a valuable tool for the quantification of cardiac amyloid burden in both ATTR and AL cardiomyopathy.
  • "AT-01 has the potential to be the first non-invasive, pan-amyloid, imaging agent designed to detect all types of systemic amyloidosis across key organs.
  • AT-01 (iodine (I-124) evuzamitide) utilizes the companys pan-amyloid binding peptide as an amyloid-specific imaging agent to image all types of systemic amyloidosis by PET/CT imaging.
  • Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.

New ASNC-led Guideline Details How to Use CT in Hybrid Nuclear-CT Cardiac Imaging

Retrieved on: 
Tuesday, September 6, 2022
American Association of Physicists in Medicine, Inflammation, PET, Guideline, ASNC, American Association, Master of Science, SPECT/CT, OnDemand, Cross, Solution, Houston Methodist Hospital, Society, Table, Molecular imaging, Physician, Journal of Nuclear Cardiology, MPI, CACS, Society of Cardiovascular Computed Tomography, Organization, Journal, Physicist, Health, American Society of Nuclear Cardiology, Collaboration, Atherosclerosis, SCCT, PET/CT, Competence, Hibernation, Knowledge, AAPM, Coronary artery disease, Hardware, Society of Nuclear Medicine and Molecular Imaging, Cardiology, Patient, SNMMI, Medical imaging, Medicine, Software, MD

FAIRFAX, Va., September 06, 2022 /PRNewswire-PRWeb/ -- The American Society of Nuclear Cardiology (ASNC) and three partner societies have come together to answer cardiac imagers' questions about SPECT/CT and PET/CT imaging with attenuation correction, localization of radiotracer uptake and coronary artery calcium scoring (CACS). In a new multisociety guideline published today in the Journal of Nuclear Cardiology, the organizations recommend training and competency requirements for imaging physicians and technologists; describe models for collaborative, cross-specialty study interpretation and reporting; and suggest solutions for the preauthorization and reimbursement challenges that some labs have faced with hybrid imaging in nuclear cardiology.

Key Points: 
  • "Assessing atherosclerosis burden in hybrid imaging improves the diagnostic accuracy of MPI studies and help clinicians identify high-risk patients and treat them accordingly.
  • The question is not whether today's cardiac imaging labs should adopt hybrid imaging but rather how to adapt their labs for the routine use of SPECT/CT and PET/CT.
  • Imaging teams will find the new guideline is a blueprint for modernizing their labs for the delivery of hybrid nuclear-CT imaging.
  • ASNC's Hybrid Imaging Symposium will be delivered in two parts:
    Part 1 is currently available OnDemand on the ASNC2022 online meeting platform.

Dr. Sharmila Dorbala Will Present Keynote Lecture at ASNC2022

Retrieved on: 
Monday, July 25, 2022
Consensus, Organ dysfunction, Diagnosis, MPH, Molecular imaging, Medical diagnosis, Muscle tissue, Health, Research, ASNC, Exhibition, PET, Hospital, Cardiac amyloidosis, TTR, Disease, Patient, Heart, Journal of Nuclear Cardiology, Heart failure, Amyloid, Radiology, American Society of Nuclear Cardiology, Brigham and Women's Hospital, Harvard Medical School, Health care, Society, Medical imaging, Medical device, MD

FAIRFAX, Va., July 25, 2022 /PRNewswire-PRWeb/ -- Cardiac imaging specialist and cardiac amyloidosis researcher Sharmila Dorbala, MD, MPH, MASNC, will present the Mario Verani Memorial Lecture at the American Society of Nuclear Cardiology (ASNC) 2022 Annual Scientific Session and Exhibition. Her lecture, titled "Molecular Imaging of Cardiac Amyloidosis: From Unraveling Pathophysiology to Transforming Patient Care," will examine how the recent paradigm shift in the diagnosis and treatment of transthyretin (TTR) cardiac amyloidosis has yielded lessons that may unlock the potential to prevent heart failure from amyloid as well as transform the care of patients with other diseases.

Key Points: 
  • Cardiac imaging specialist and cardiac amyloidosis researcher Sharmila Dorbala, MD, MPH, MASNC, will present the Mario Verani Memorial Lecture at the American Society of Nuclear Cardiology (ASNC) 2022 Annual Scientific Session and Exhibition.
  • FAIRFAX, Va., July 25, 2022 /PRNewswire-PRWeb/ -- Cardiac imaging specialist and cardiac amyloidosis researcher Sharmila Dorbala, MD, MPH, MASNC, will present the Mario Verani Memorial Lecture at the American Society of Nuclear Cardiology (ASNC) 2022 Annual Scientific Session and Exhibition .
  • "Molecular imaging is the key to understanding the precise pathophysiology of cardiac amyloidosis and various other diseases," Dr. Dorbala says.
  • Dr. Dorbala will present the Mario Verani Memorial Lecture on Sept. 9 during the Opening Plenary Session.